Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Carfilzomib · Kyprolis, NSC-758252

Small molecule · Inhibitor of 20S proteasome · developed by Onyx Pharms Amgen

Approved FDA, Jul 2012

AMGN Developer

1 Registered trials

What is Carfilzomib?

Carfilzomib is a tetrapeptide epoxyketone that irreversibly inhibits the 20S proteasome. It has antiproliferative and proapoptotic activities in tumor cells and delayed tumor growth in multiple myeloma models.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Kyprolis, NSC-758252, PR-171
Drug type: Small molecule
Targets: 20S proteasome
Mechanism: Inhibitor of 20S proteasome
Pathways: proteasome inhibition, apoptosis
Therapy area: Oncology
Developer: Onyx Pharms Amgen (AMGN)
FDA status: Approved as Kyprolis (July 20, 2012), NDA202714 · FDA label
UNII: 72X6E3J5AR

✅ FDA-approved uses

Relapsed or refractory multiple myeloma

From the indications section of the FDA label (version of Jun 18, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05789303	Phase 2	Multiple Myeloma	Recruiting	AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple MyelomaRelapse Multiple Myeloma

More from Onyx Pharms Amgen

Apremilast FDA approved Blinatumomab FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Carfilzomib

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z